Monoclonal antibody 3S193 - Recepta biopharma

Drug Profile

Monoclonal antibody 3S193 - Recepta biopharma

Alternative Names: 3S193; Anti-Lewis Y monoclonal antibody 3S193; hu3S193; Hu3S193 - RECEPTA biopharma; mAb Hu3S193 - Anti-LeY; RebmAb 100

Latest Information Update: 17 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer Recepta biopharma; University of Sao Paulo
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Lewis Y antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 06 Jun 2017 Efficacy and adverse events data from a phase II trial in Ovarian cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 16 Nov 2015 Recepta Biopharma terminates a phase II trial in Ovarian cancer (Second-line therapy or greater, Platinum resistant/refractory) in Brazil since the total number of patients expected to be enrolled was not met (NCT01137071)
  • 12 Aug 2015 Recepta biopharma suspends patient enrolment in a phase II trial for Breast cancer (late-stage disease, second line therapy or greater) in Brazil (NCT01370239)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top